Table 2.
Clinical Characteristics of the Validation Phase Patients of subgroups varied according to ejection fraction, comparing to healthy controls.
| Characteristics | Control | DCM | DCM EF > 55% | DCM EF ≤ 55% |
|---|---|---|---|---|
| (n = 16) | (n = 30) | (n = 15) | (n = 15) | |
| Age | ||||
| Mean ± SD,yrs | 5.97 ± 4.41 | 4.15 ± 3.85 | 3.97 ± 2.79 | 4.33 ± 4.77 |
| Median,yrs | 4.5 | 3 | 3 | 2 |
| Age group (n, %) | ||||
| <1 yrs | 2(12.50) | 9(30.00) | 3(20.00) | 6(40.00) |
| 1~10yrs | 10(62.50) | 18(60.00) | 12(80.00) | 6(40.00) |
| >10yrs | 4(25.00) | 3(10.00) | 0 | 3(20.00) |
| Male (n,%) | 9(56.25) | 13(43.33) | 7(46.67) | 6(40.00) |
| EF (%) | 65.19 ± 13.58 | 50.20 ± 17.24* | 66.53 ± 2.95 | 33.87 ± 5.91*# |
| LVDD (mm) | 35.06 ± 5.13 | 44.63 ± 12.69* | 39.53 ± 8.41 | 49.73 ± 14.41*# |
| FS (%) | 32.56 ± 6.78 | 25.10 ± 8.62* | 33.27 ± 1.47 | 16.93 ± 2.95*# |
| Creatinine(umol/L) | 34.24 ± 10.97 | 30.17 ± 13.00 | 28.37 ± 11.17 | 31.97 ± 14.78 |
| Glucose(mmol/L) | 4.60 ± 0.52 | 4.82 ± 0.53 | 4.69 ± 0.55 | 4.96 ± 0.49 |
| Total glyceride(mmol/L) | 0.90 ± 0.80 | 0.88 ± 0.43 | 1.03 ± 0.41 | 0.73 ± 0.40 |
| Total cholesterol (mmol/L) | 4.26 ± 0.81 | 4.01 ± 0.84 | 4.03 ± 0.87 | 3.99 ± 0.85 |
| HDL cholesterol (mmol/L) | 1.32 ± 0.42 | 1.37 ± 0.34 | 1.39 ± 0.40 | 1.36 ± 0.26 |
| LDL cholesterol (mmol/L) | 2.53 ± 0.65 | 2.25 ± 0.74 | 2.20 ± 0.78 | 2.31 ± 0.72 |
Values are mean ± SD or n(%). The p values are quoted for the Kruskal-Wallis or chi-square tests for continuous or categorical variables, respectively.
Comparative with healthy controls, *P < 0.05; Comparative with DCM EF ≤ 55%, #P < 0.05.
DCM: dilated cardiomyopathy; EF: Ejection Fractions; FS: fractionalshortening; HDL: high-density lipoprotein; LVEDD: left ventricular end-diastolic dimension; LDL: low-density lipoprotein.